Athira Pharma Announces Reverse Stock Split

Core Viewpoint - Athira Pharma, Inc. will implement a 10-for-1 reverse stock split to comply with Nasdaq's minimum bid price requirement and enhance the marketability and liquidity of its common stock [1][2][3]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect on September 17, 2025, at 5:00 p.m. Eastern Time, with trading on a split-adjusted basis starting on September 18, 2025 [2]. - Every ten shares of Athira's common stock will be combined into one share, reducing the total number of authorized shares from 900 million to 90 million [3]. - The par value per share will remain unchanged at $0.0001, and adjustments will be made to outstanding options and restricted stock units [3]. Group 2: Impact and Purpose - The reverse stock split aims to increase the share price to meet the $1.00 minimum bid price requirement for continued listing on Nasdaq [2]. - The company anticipates that the split will improve the marketability and liquidity of its common stock, potentially attracting a broader range of investors [2][3]. Group 3: Administrative Aspects - Computershare Inc. will act as the exchange agent for the reverse stock split, and registered stockholders will not need to take action to receive post-split shares [4]. - Stockholders holding shares in brokerage accounts will have their positions automatically adjusted to reflect the reverse stock split [4].